ARQT vs. OPK, SPRY, ABVX, OCUL, IMNM, PRAX, ETNB, TYRA, ALXO, and SAVA
Should you be buying Arcutis Biotherapeutics stock or one of its competitors? The main competitors of Arcutis Biotherapeutics include OPKO Health (OPK), ARS Pharmaceuticals (SPRY), ABIVAX Société Anonyme (ABVX), Ocular Therapeutix (OCUL), Immunome (IMNM), Praxis Precision Medicines (PRAX), 89bio (ETNB), Tyra Biosciences (TYRA), ALX Oncology (ALXO), and Cassava Sciences (SAVA). These companies are all part of the "pharmaceutical preparations" industry.
OPKO Health (NASDAQ:OPK) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, media sentiment, risk, profitability, analyst recommendations, valuation and community ranking.
OPKO Health has a net margin of -21.76% compared to OPKO Health's net margin of -439.79%. Arcutis Biotherapeutics' return on equity of -12.69% beat OPKO Health's return on equity.
OPKO Health received 446 more outperform votes than Arcutis Biotherapeutics when rated by MarketBeat users. Likewise, 65.87% of users gave OPKO Health an outperform vote while only 61.18% of users gave Arcutis Biotherapeutics an outperform vote.
OPKO Health has higher revenue and earnings than Arcutis Biotherapeutics. OPKO Health is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
64.6% of OPKO Health shares are held by institutional investors. 47.3% of OPKO Health shares are held by company insiders. Comparatively, 20.7% of Arcutis Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
OPKO Health currently has a consensus price target of $3.17, indicating a potential upside of 147.40%. Arcutis Biotherapeutics has a consensus price target of $26.56, indicating a potential upside of 238.72%. Given OPKO Health's higher possible upside, analysts clearly believe Arcutis Biotherapeutics is more favorable than OPKO Health.
In the previous week, OPKO Health had 6 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 14 mentions for OPKO Health and 8 mentions for Arcutis Biotherapeutics. OPKO Health's average media sentiment score of 0.49 beat Arcutis Biotherapeutics' score of -0.28 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media.
OPKO Health has a beta of 1.81, suggesting that its share price is 81% more volatile than the S&P 500. Comparatively, Arcutis Biotherapeutics has a beta of 1.18, suggesting that its share price is 18% more volatile than the S&P 500.
Summary
OPKO Health beats Arcutis Biotherapeutics on 13 of the 18 factors compared between the two stocks.
Get Arcutis Biotherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ARQT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ARQT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Arcutis Biotherapeutics Competitors List
Related Companies and Tools
